Literature DB >> 35876876

Acetyl-DL-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?

Sandra Becker-Bense1, Lena Kaiser2, Regina Becker3, Katharina Feil4,3, Carolin Muth4,3, Nathalie L Albert2, Marcus Unterrainer5, Peter Bartenstein2,6, Michael Strupp3, Marianne Dieterich4,3,6.   

Abstract

OBJECTIVE: The aim of the study was to deepen our insights into central compensatory processes of brain networks in patients with cerebellar ataxia (CA) before and with treatment with acetyl-DL-leucine (AL) by means of resting-state [18F]-FDG-PET brain imaging.
METHODS: Retrospective analyses of [18F]-FDG-PET data in 22 patients with CA (with vestibular and ocular motor disturbances) of different etiologies who were scanned before (PET A) and on AL treatment (PET B). Group subtraction analyses, e.g., for responders and non-responders, comparisons with healthy controls and correlation analyses of regional cerebral glucose metabolism (rCGM) with symptom duration, ataxia (SARA) and quality of life (QoL) scores were calculated.
RESULTS: Prior to treatment rCGM was consistently downregulated at the cerebellar level and increased in multisensory cortical areas, e.g., somatosensory, primary and secondary visual (including V5, precuneus), secondary vestibular (temporal gyrus, anterior insula), and premotor/supplementary motor areas. With AL (PET B vs. A) cerebellar hypometabolism was deepened and sensorimotor hypermetabolism increased only in responders with clinical benefit, but not for the non-responders and the whole CA group. A positive correlation of ataxia improvement with rCGM was found in visual and vestibular cortices, a negative correlation in cerebellar and brainstem areas. QoL showed a positive correlation with rCGM in the cerebellum and symptom duration in premotor and somatosensory areas.
CONCLUSIONS: Central compensatory processes in CA mainly involve multisensory visual, vestibular, and somatosensory networks as well as premotor/primary motor areas at the cortical level. The enhanced divergence of cortical sensorimotor up- and cerebellar downregulation with AL in responders could reflect amplification of inhibitory cerebellar mechanisms.
© 2022. The Author(s).

Entities:  

Keywords:  Acetyl-DL-leucine; Ataxia; Cerebellum; Compensation; PET; Treatment; Vestibular

Year:  2022        PMID: 35876876     DOI: 10.1007/s00415-022-11252-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  36 in total

Review 1.  Consensus Paper: Neurophysiological Assessments of Ataxias in Daily Practice.

Authors:  W Ilg; M Branscheidt; A Butala; P Celnik; L de Paola; F B Horak; L Schöls; H A G Teive; A P Vogel; D S Zee; D Timmann
Journal:  Cerebellum       Date:  2018-10       Impact factor: 3.847

2.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

3.  The neurological update: therapies for cerebellar ataxias in 2020.

Authors:  J Gandini; Mario Manto; T Bremova-Ertl; K Feil; M Strupp
Journal:  J Neurol       Date:  2020-01-30       Impact factor: 4.849

Review 4.  Consensus Paper: Revisiting the Symptoms and Signs of Cerebellar Syndrome.

Authors:  Florian Bodranghien; Amy Bastian; Carlo Casali; Mark Hallett; Elan D Louis; Mario Manto; Peter Mariën; Dennis A Nowak; Jeremy D Schmahmann; Mariano Serrao; Katharina Marie Steiner; Michael Strupp; Caroline Tilikete; Dagmar Timmann; Kim van Dun
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

5.  Acetyl-dl-leucine in Niemann-Pick type C: A case series.

Authors:  Tatiana Bremova; Věra Malinová; Yasmina Amraoui; Eugen Mengel; Jörg Reinke; Miriam Kolníková; Michael Strupp
Journal:  Neurology       Date:  2015-09-23       Impact factor: 9.910

6.  Consensus paper: management of degenerative cerebellar disorders.

Authors:  W Ilg; A J Bastian; S Boesch; R G Burciu; P Celnik; J Claaßen; K Feil; R Kalla; I Miyai; W Nachbauer; L Schöls; M Strupp; M Synofzik; J Teufel; D Timmann
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

7.  Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series.

Authors:  Michael Strupp; Julian Teufel; Maximilian Habs; Regina Feuerecker; Carolin Muth; Bart P van de Warrenburg; Thomas Klopstock; Katharina Feil
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

8.  Acetyl-leucine slows disease progression in lysosomal storage disorders.

Authors:  Ecem Kaya; David A Smith; Claire Smith; Lauren Morris; Tatiana Bremova-Ertl; Mario Cortina-Borja; Paul Fineran; Karl J Morten; Joanna Poulton; Barry Boland; John Spencer; Michael Strupp; Frances M Platt
Journal:  Brain Commun       Date:  2020-12-20

9.  Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.

Authors:  Roman Schniepp; Michael Strupp; Max Wuehr; Klaus Jahn; Marianne Dieterich; Thomas Brandt; Katharina Feil
Journal:  Cerebellum Ataxias       Date:  2016-04-12

Review 10.  Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.

Authors:  Roger Kalla; Michael Strupp
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.